Randomized, double-blind, dose-ranging trial of the oral neurokinin-1 receptor antagonist casopitant mesylate for the prevention of cisplatin-induced nausea and vomiting.
about
Neurokinin-1 inhibitors in the prevention of nausea and vomiting from highly emetogenic chemotherapy: a network meta-analysisGuideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference.The substance P/NK-1 receptor system: NK-1 receptor antagonists as anti-cancer drugs.Involvement of substance P and the NK-1 receptor in pancreatic cancer.NK-1 as a melanoma target.Fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting.Neurokinin-1 receptor antagonists for chemotherapy-induced nausea and vomiting: a systematic review.Safety of neurokinin-1 receptor antagonists.Comparative effectiveness research in antineoplastic-induced nausea and vomiting control in children.Defining the efficacy of neurokinin-1 receptor antagonists in controlling chemotherapy-induced nausea and vomiting in different emetogenic settings-a meta-analysis.Rolapitant: a pooled analysis of its efficacy and safety in the prophylaxis of chemotherapy-induced nausea and vomiting.Neurokinin-1 Receptor Antagonist-Based Triple Regimens in Preventing Chemotherapy-Induced Nausea and Vomiting: A Network Meta-Analysis.Clinical pharmacology of neurokinin-1 receptor antagonists for the treatment of nausea and vomiting associated with chemotherapy.Olanzapine-Based Triple Regimens Versus Neurokinin-1 Receptor Antagonist-Based Triple Regimens in Preventing Chemotherapy-Induced Nausea and Vomiting Associated with Highly Emetogenic Chemotherapy: A Network Meta-Analysis.Adherence to national guidelines for antiemesis prophylaxis in patients undergoing chemotherapy for lung cancer
P2860
Q28078513-E589C305-8D4E-49F7-8B87-8436BF23730FQ34121232-F70B1202-979B-4C82-9A37-24DADAE8A8C8Q34475975-5514E1C0-009E-4674-AB1D-968FD713808FQ37617971-98D5DFEC-B9F1-4771-923C-B94A8653E7F7Q37876914-9DC7CBE3-1CC0-4E49-A167-CCDA32357484Q37982438-D61D30B1-4CA4-4537-A83B-501434958D80Q38036613-3655335D-5047-4A4A-A4CC-A6329AFDB331Q38109245-27712DAE-1537-46D5-881A-4E17B41C697FQ38197218-B772955F-08B6-4229-AE02-FF4A3F75991AQ38609969-4BBC17E3-8495-4433-A582-C32E4622B578Q38710356-D6342218-FDD7-40A0-8CE6-F6B73DF0CF90Q38994391-8D196044-B2E3-4E0F-BE97-2CF9AF312243Q39275766-2E8E0156-E46D-4422-B130-1DADDE4D3518Q48251989-951DF967-B379-4D38-B0CC-78C14A9FF5A4Q57304425-AA1C6084-BD8D-4E81-B9AD-6C708EA4AB2D
P2860
Randomized, double-blind, dose-ranging trial of the oral neurokinin-1 receptor antagonist casopitant mesylate for the prevention of cisplatin-induced nausea and vomiting.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Randomized, double-blind, dose ...... n-induced nausea and vomiting.
@ast
Randomized, double-blind, dose ...... n-induced nausea and vomiting.
@en
Randomized, double-blind, dose ...... n-induced nausea and vomiting.
@nl
type
label
Randomized, double-blind, dose ...... n-induced nausea and vomiting.
@ast
Randomized, double-blind, dose ...... n-induced nausea and vomiting.
@en
Randomized, double-blind, dose ...... n-induced nausea and vomiting.
@nl
prefLabel
Randomized, double-blind, dose ...... n-induced nausea and vomiting.
@ast
Randomized, double-blind, dose ...... n-induced nausea and vomiting.
@en
Randomized, double-blind, dose ...... n-induced nausea and vomiting.
@nl
P2093
P356
P1433
P1476
Randomized, double-blind, dose ...... in-induced nausea and vomiting
@en
P2093
P304
P356
10.1093/ANNONC/MDP194
P577
2009-06-18T00:00:00Z